Compare Coursera Inc (COUR) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coursera Inc vs Inovio Pharmaceuticals Inc — how do they compare? Coursera Inc trades at $5.23 (market cap $1.39B), while Inovio Pharmaceuticals Inc trades at $1.1 (market cap $112.19M). The key difference: Coursera Inc is far larger — about 12.4× Inovio Pharmaceuticals Inc's market cap, and Inovio Pharmaceuticals Inc is trading nearer its 52-week high, Coursera Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Coursera Inc for 47 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| COUR | INO | |
|---|---|---|
Market Cap | $1.39B | $112.19M |
Volume | 9,728,980 | 3,201,278 |
Sector | Consumer Staples | Health |
52-Week High | $10.73 | $2.65 |
52-Week Low | $4.64 | $0.66 |
Typical Hold Time | 47 Days | 43 Days |
Enterprise Value | $648.49M | $83.51M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coursera (COUR) trades at $5.235, up 2.45% today, with a mixed technical outlook showing a bullish overall signal but bearish moving averages. Revenue has grown steadily from $524M in 2022 to $758M in 2025, though the company remains unprofitable with a net loss of $51M in 2025. Recent news highlights strong institutional interest, including a 137% surge in call option volume (Defense World, 2026-10-01) and the launch of Project Helix, an AI-native learning platform (Business Wire, 2026-09-09).
The stock offers upside to the $7.40 analyst consensus target but faces risks from persistent losses and integration challenges. Positive cash flow and subscriber growth are key strengths, yet profitability remains elusive. Investors should weigh the 52.94% buy rating against high RSI levels and competitive pressures in the edtech sector.
Inovio Pharmaceuticals (INO) trades at $1.09, down 5.63% today, reflecting ongoing financial challenges with minimal revenue of $65,340 in 2025 and substantial losses. The company shows consistent negative cash flow from operations but has beaten EPS estimates in recent quarters. Technical indicators are bearish, with moving averages and oscillators signaling selling pressure. Key near-term catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, its lead candidate for recurrent respiratory papillomatosis.
The investment case hinges on FDA approval of INO-3107, with analyst consensus target at $2.75 offering significant upside. However, high burn rate, negative margins, and dependence on financing pose substantial risks. Positive regulatory outcome could drive revaluation, but failure may exacerbate financial strain. Wall Street maintains cautious optimism with 59% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Coursera Inc
Coursera Inc is a global online learning platform that offers anyone, anywhere access to online courses and degrees from world-class universities and companies. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The platform will contain a catalog of high-quality content and credentials, content developed by leading university and industry partners, data and machine learning drive personalized Learning, effective marketing, and skills Benchmarking and others.
Read more on COUR →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
